Chemistry:Pidilizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | DLL1 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6424H9920N1704O2002S48 |
| Molar mass | 144594.83 g·mol−1 |
Pidilizumab (formerly CT-011) is a monoclonal antibody being developed by Medivation for the treatment of cancer and infectious diseases.[1][2] Pidilizumab was originally thought to bind to the PD-1 immune checkpoint molecule, however, recent evidence suggests that Delta-like 1 (DLL1) is its primary binding target while binding to PD-1 is secondary and restricted to non-glycosylated and hypoglycosylated forms of this molecule.[3] Pidilizumab causes in the attenuation of apoptotic processes in lymphocytes, primarily effector/memory T cells.
Clinical trials
It had encouraging results by 2011 from phase II clinical trials for diffuse large B-cell lymphoma.[4] A phase II open-label study in combination for relapsed follicular lymphoma found good results compared to usual response rates. A phase I/II open label study in pediatric patients with a rare form of brain cancer, diffuse intrinsic pontine glioma, found improvement in overall survival compared to expected outcome.[citation needed] An add-on trial for multiple myeloma is ongoing.[5]
References
- ↑ "Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial". The Lancet. Oncology 15 (1): 69–77. January 2014. doi:10.1016/S1470-2045(13)70551-5. PMID 24332512.
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Pidilizumab, American Medical Association- needs login.
- ↑ Carroll, John (26 January 2016). "Anti-PD-1? Well, no, says Medivation as a partial hold forces a halt to 'pivotal' cancer study". Fierce Biotech. http://www.fiercebiotech.com/story/anti-pd-1-well-no-says-medivation-partial-hold-forces-halt-pivotal-cancer-s/2016-01-26.
- ↑ "Teva Invests $19M More in CureTech After Positive Phase II DLBCL Data". Genetic Engineering & Biotechnology News. September 2011. http://www.genengnews.com/gen-news-highlights/teva-invests-19m-more-in-curetech-after-positive-phase-ii-dlbcl-data/81245673/.
- ↑ Clinical trial number NCT02077959 for "Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma" at ClinicalTrials.gov
 |  |
